Y-mAbs Therapeutics Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Mike Rossi

Geschäftsführender

US$3.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	3.5%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.8yrs

Jüngste Management Updates

Recent updates

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Sep 12

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mike Rossi im Vergleich zu den Einnahmen von Y-mAbs Therapeutics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	US$3m	US$110k	-US$21m

Vergütung im Vergleich zum Markt: MikeDie Gesamtvergütung ($USD3.11M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD2.39M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Mike mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Mike Rossi (53 yo)

less than a year

Amtszeit

US$3,110,553

Vergütung

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	keine Daten
Thomas Gad	Founder	9.4yrs	US$2.45m	0.58% $ 3.4m
Susan Smith	Senior VP & Chief Commercial Officer	2.7yrs	US$887.28k	0.0095% $ 55.1k
Peter Pfreundschuh	CFO & Treasurer	less than a year	keine Daten	keine Daten
Joris Wiel Wilms	Senior VP & COO	6.8yrs	keine Daten	0.0021% $ 12.1k
Torben Lund-Hansen	Senior VP & CTO	8.7yrs	keine Daten	0.12% $ 668.1k
Courtney Dugan	Vice President of Investor Relations	no data	keine Daten	keine Daten
Vignesh Rajah	Senior VP & Chief Medical Officer	4.3yrs	US$724.92k	0.019% $ 109.9k
Norman D. LaFrance	Chief Development Officer	less than a year	keine Daten	keine Daten

3.5yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: YMABDas Führungsteam des Unternehmens gilt als erfahren (4.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Rossi	CEO, President & Director	less than a year	US$3.11m	keine Daten
Thomas Gad	Founder	9.4yrs	US$2.45m	0.58% $ 3.4m
James Healy	Independent Chairman of the Board	6.8yrs	US$184.31k	0.063% $ 364.0k
David Gill	Independent Director	6.8yrs	US$180.56k	0.0052% $ 30.2k
Mary Tagliaferri	Director	less than a year	keine Daten	0% $ 0
Johan Wedell-Wedellsborg	Independent Director	9yrs	US$158.06k	0.0052% $ 30.2k
Ashutosh Tyagi	Independent Director	6.8yrs	US$158.06k	0.0052% $ 30.2k
Laura Hamill	Independent Director	4.3yrs	US$168.06k	0.0052% $ 30.2k

6.8yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrener Vorstand: YMABDie Vorstandsmitglieder gelten als erfahren (6.5 Jahre durchschnittliche Amtszeit).

Y-mAbs Therapeutics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Founder recently sold US$1.3m worth of stock

Founder notifies of intention to sell stock

Senior VP & CTO notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Recent updates

Founder recently sold US$1.3m worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Held Back By Insufficient Growth Even After Shares Climb 33%

Senior VP & CTO notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Second quarter 2024 earnings: EPS misses analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.(NasdaqGS:YMAB) dropped from Russell Small Cap Comp Value Index

Y-mAbs Therapeutics, Inc. Announces the Appointment of Peter Pfreundschuh as Chief Financial Officer

Founder notifies of intention to sell stock

Founder recently sold US$841k worth of stock

Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Executive VP notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Announces New Interim Analysis of Phase 2 Data for Naxitamab At 2024 Asco Annual Meeting

Founder recently sold US$396k worth of stock

Founder notifies of intention to sell stock

Y-mAbs: There's A Ceiling Here Somewhere

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Y-mAbs Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Y-mAbs Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Y-mAbs Therapeutics, Inc. Announces Resignation of Bo Kruse as Executive Vice President, Secretary and Treasurer, Effective July 31, 2024

Y-mAbs Therapeutics Announces Resignation of Bo Kruse as Chief Financial Officer

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Consensus estimates of losses per share improve by 42%

Y-mAbs Therapeutics, Inc. Appoints Mary Tagliaferri to Its Board of Directors

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Y-mAbs Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Price target increased by 9.3% to US$13.67

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Founder exercised options to buy US$370k worth of stock.

Founder recently sold US$1.0m worth of stock

Founder notifies of intention to sell stock

Founder recently sold US$795k worth of stock

Founder notifies of intention to sell stock

Y-mAbs Therapeutics, Inc. Reiterates Financial Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Y-mAbs Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Y-mAbs Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective from November 6, 2023

Y-mAbs Therapeutics, Inc. Announces Publication of Naxitamab-Based Chemoimmunotherapy in Patients with Chemoresistant High-Risk Neuroblastoma

Consensus EPS estimates upgraded to US$0.70 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Revenue and earnings growth

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Y-mAbs Therapeutics, Inc. Announces DANYELZA (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in Brazil

Consensus revenue estimates increase by 27%

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Price target increased by 11% to US$10.50

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics, Inc. Updates Financial Guidance for the Full-Year 2023

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Consensus estimates of losses per share improve by 14%

Price target decreased by 15% to US$9.14

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Y-mAbs Therapeutics, Inc. and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab

Rosen Law Firm Encourages Y-Mabs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB

Price target decreased to US$10.88

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Y-mAbs Therapeutics, Inc. Announces National Medical Products Administration in China Has Granted Danyelza 40Mg/10Ml Conditional Approval

Y-mAbs Therapeutics, Inc. Announces Complete Response Letter for Omburtamab Biologics License Application